Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CMP 001

Drug Profile

CMP 001

Alternative Names: ARB 1598; CMP-001; CYT 003 QbetaG10; CYT-003; CYT003 PolQb; CYT003 PolQbeta; CYT003-QbG10; Immunodrug™ CYT003-QbG10; QbG10; Virus-like particle-based cancer vaccine - Checkmate; VLP-based cancer vaccine - Checkmate

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytos Biotechnology
  • Developer Arbutus Biopharma; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Cytos Biotechnology; University of Pittsburgh
  • Class Allergy immunotherapies; Antiallergics; Cancer vaccines; Oligonucleotides; Virus-like particle vaccines
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Colorectal cancer; Non-small cell lung cancer
  • Preclinical Lymphoma
  • Discontinued Allergic asthma; Atopic dermatitis; Hepatitis B; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 15 Dec 2018 Phase-I clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Israel (SC) (NCT03507699)
  • 15 Dec 2018 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Recurrent, Combination therapy, Second-line therapy or greater) in Israel (Intratumoural) (NCT03507699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top